As part of a collaborative study on toxicity related to female fertility, we performed experiments using di-(2-ethylhexyl) phthalate (DEHP), widely used as a plasticizer of polyvinyl chloride (PVC) and a known peroxisome proliferator (Lake et al., 1987) , liver carcinogen (Reddy and Lalwai, 1983) and ovarian toxicant in rodents (Davis et al., 1994) . Short-term exposure to DEHP resulted in hypoestrogenic anovulatory cycles and polycystic ovaries in adult rats (Davis et al., 1994) . Longterm exposure to DEHP resulted in continuous diestrous stage with reduced serum estradiol, follicle stimulating hormone (FSH), pituitary FSH and luteinizing hormone (LH) (Hirosawa et al., 2006) . The active metabolite of DEHP mono-(2-ethylhexyl) phthalate (MEHP) decreased aromatase in rat granulosa cells in vitro (Davis et al., 1994) . Because the toxic effects of DEHP on ovaries are thought to be endocrine disorders and an aromatase inhibitor is expected to impact both ovarian morphology and female fertility, we selected DEHP as the test compound for the evaluation of ovarian toxicity.
INTRODUCTION
suspended in corn oil and the dose volume set at 0.5 ml/100 g of body weight. Control animals were given the vehicle solution at the same dosage.
Animals
SPF Sprague Dawley female and male rats were purchased from Charles River Laboratories Japan, Inc. (Tokyo, Japan). The animals were housed in a room maintained at 20-26°C and a relative humidity of 35-75%, with lights on from 7:00 to 19:00 and 14-16 air changes per an hour. All animals were allowed free access to commercial rodent chow, CE-2 (CLEA Japan, Tokyo, Japan), and to tap water. All procedures associated with this study were approved by the Institutional Animal Care and Use Committee at the test facility. This study was conducted following the principle stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996 . The test facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.
Study design

Repeated-dose toxicity studies
DEHP was orally administered to female rats at dose levels of 0, 300, 1,000 and 3,000 mg/kg for 2 and 4 weeks. Each group consisted of 10 animals. The animals were observed daily for general conditions, and body weights were measured once every 3 to 4 days. Estrous cycles were determined every day by vaginal smear. On the day of necropsy, all animals were anesthetized with After exsanguination, the thoracic and abdominal organs were examined macroscopically. Then, from each animal, the ovaries, uterus, vagina, liver, kidney, adrenal glands -specimens for histopathology were prepared and stained with hematoxylin and eosin (HE) according to standard procedures. Immunohistochemistry using Dako anti-proliferation cell nuclear antigen (PCNA) antibody (clone: PC10) was also performed on the ovaries. The prepared histopathological specimens were examined under light microscopy. At dissection, bilateral ovaries were transversally halved to observe the maximum area of the ovary.
Female fertility study DEHP was orally administered to female rats at dose levels of 0, 300, 1,000 and 3,000 mg/kg for 2 weeks before mating. Each group consisted of 10 animals of each sex. Males were not treated and used only for mating purpose. After 2 weeks of administration, females were cohabited with nontreated males for up to 2 weeks. In addition, a vaginal smear was collected from all females during the pre-mating period and the estrous cycle evaluated. Daily dosing of DEHP or vehicle was continued throughout the mating period and until Day 7 of pregnancy (the day of copulation was designated as Day 0 of pregnancy). Animals were necropsied on Day 13 of pregnancy, and the thoracic and abdominal organs were examined macroscopically. The number of corpora lutea, implantations and live and dead embryos were counted and the copulation and pregnancy rates calculated.
Statistical analyses
Statistical analyses were performed by the Provantis 7 system (Instem LSS Ltd., Liverpool, UK) and the SAS preclinical package software version 5.0 (SAS system 8.02; SAS Institute Japan Ltd., Tokyo, Japan). For body weight and mean estrous cycle, the decision tree procedure of the Provantis 7 system was used in which the best transformation for each variable in terms of homogeneity, kurtosis and group size is selected. If nontransformation or log transformation was selected, a Williams test --ference was observed by one-way analysis of variance, Dunnett's multiple comparison test was performed. If rank transformation was selected as the best transforma---cant difference observed from the Kruskal Wallis test, the non-parametric Dunnett's multiple comparison test was performed. Data of food consumption was evaluated by Dunnett's multiple comparison test; implantation and corpora lutea count, pre-and post-implantation loss rate, and number of live and dead embryos analyzed by Kruskal Wallis test. Rates of copulation, pregnancy and irregular estrous cycle were determined by Fisher's exact test. In
RESULTS
Repeated-dose toxicity studies
No animals in any of the groups died during the 2-and 4-week studies. Smudge of lower abdomen area was found in the 3,000 mg/kg group of the 2-week study. In the 4-week study, salivation was observed at 1,000 mg/kg and, at 3,000 mg/kg, salivation, smudge of lower abdomen and peri-mouth areas, loose feces, and decrease of feces was observed.
In addition, lower body weight was observed in the 3,000 mg/kg group of the 4-week study. At the estrous cycle, increase of irregular estrous cycles and prolongation of mean estrus cycles were observed in the 3,000 mg/kg group of the 4-week study (Tables 1 and 2 ). An increase in liver weight was observed with dosages of 1,000 mg/kg and higher in the 2-week study and of 300 mg/kg and higher in the 4-week study. A decrease in pituitary grand weight was observed at 3,000 mg/kg in both the 2-and 4-week studies (Tables 3 and 4) . At necropsy, enlargement of the liver was observed at 1,000 mg/kg and higher in the 2-week study and in all dosage groups of the 4-week study and enlarged adrenal gland was observed in the 3,000 mg/kg group of the 2-week study. Small uterus, dilatation and discolored areas of the kidney were observed in the 3,000 mg/kg group of the 4-week study (Tables 5 and 6 ). Histopathological abnormalities were observed in the ovary, uterus, vagina, kidney, adrenal glands, pituitary gland and liver in the 2-and/or 4-week studies (Tables 5  and 6 ). In the ovary in both studies, vacuolation of stromal cells was observed in groups receiving 300 mg/kg or more and increased large atretic follicle was observed with doses of 1,000 mg/kg and higher. A decrease in new corpora lutea was observed in the 3,000 mg/kg group of the 4-week study (Fig. 1) . Atrophy in the uterus and thinning of the epithelium with mucinification of the vagina were observed in the 3,000 mg/kg group of the 4-week study. In the liver, hypertrophy with eosinophilic cytoplasm of hepatocytes was observed at 300 mg/kg and higher and necrosis of hepatocytes was observed at 3,000 mg/kg in both the 2-and 4-week studies. In adrenal gland, increased mitosis of fasciculate cells was observed in the 3,000 mg/kg group in the 2-week study, vacuolation of the glomerulosa cells was observed at 1,000 mg/ kg and higher and hypertrophy of the fasciculate cells in the 3,000 mg/kg group in the 4-week study. In the kidney, eosinophilic cytoplasm of proximal tubules was observed at 1,000 mg/kg and higher in the 2-week study and at 300 mg/kg and higher in the 4-week study. Renal pelvis dilatation and hyperplasia of the transition epithelium of the renal pelvis and in the pituitary gland a decrease in eosinophilic granules of acidophils was observed at 3,000 mg/ kg in the 4-week study.
Female fertility study
No animals died in any of the dose groups. Loose feces, mucous feces and salivation were observed in groups receiving 1,000 mg/kg or more and grayish feces, decrease of feces, smudging on the lower abdomen area, loss of fur and wasting were observed in the 3,000 mg/kg groups.
Lower body weights were observed in the 1,000 mg/ kg and higher groups. Food consumption decreased in the 3,000 mg/kg group during the pre-mating period. At the estrous cycle, irregular estrous cycles and prolongation of the mean estrus cycle were observed in the 3,000 mg/ kg group. The prolongation of the mean estrous cycle was observed in the 300 and 1,000 mg/kg groups, but none of the animals exhibited irregular estrous cycles and the cycles were all within the normal range (4 or 5 days). Therefore, prolongation of the mean estrous cycle in the 300 and 1,000 mg/kg groups was concluded to not be tox--dent and copulation occurred with all animals. At cesar- 
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ean section, 3 animals in 3,000 mg/kg group were found to have not become pregnant. However, the number of corpora lutea, implantation, pre-implantation loss and post implantation loss was not affected in any of the dose groups. At necropsy of the dams, enlarged liver was observed in the 300 mg/kg and higher groups (Table 7) .
DISCUSSION
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that are activated by binding of natural ligands, such as polyunsaturated fatty acids or synthetic ligands (Froment et al. is expressed in the pituitary gland of mouse and sheep (Heaney et al., 2003; Mouihate et al., 2004) and in the rat hypothalamus (Mouihate et al. to have antiproliferative effects in pituitary cells (Heaney et al., 2003) . Furthermore, decrease in pituitary gland weight is considered to be from DEHP-or MEHP (active suppressing aromatase (Lovekamp-Swan et al., 2003) . A: Stromal cells in control group in 4-week study. HE staining. B: Vacuolation of stromal cell was observed in the 3,000 mg/kg groupin 4-week study. HE staining. C: Increase of large atretic follicle was observed in 3,000mg/kg group in 4-week study. HE staining. D: A serially sectioned specimen of C. Anti-PCNA immunohistochemical staining using labeled streptavidin-biotin method. Estrous cycle stage; diestrous. *: Large atretic follicle Table 7 . Female fertility study Interval between estrous cycles was longer than 5 days or anestrous.
Therefore, the decrease in pituitary weight observed in the present toxicity study was considered to be an anti--ence on the luteinization of granulosa cells (Komar et al., 2001) and long term exposure to DEHP resulted in continuous diestrous stage with reduced serum estradiol, FSH, pituitary FSH and LH (Hirosawa et al., 2006) . Prolongation of the estrus cycle and decrease in the pregnancy rate in the present toxicity and fertility studies were consid--tion by DEHP. An increase in liver weight (Klimisch et al., 1992) and induction of cytochrome P-450 (Dirven et al., 1990 ) from administration of DEHP have been reported and the enlarged liver and increase in liver weight in the present study are consistent with above reports.
In both of the repeated-dose toxicity studies, the increases of large atretic follicles are observed at 1,000 mg/kg and higher groups. Although their incidences -tion-dependent in tendency. In addition, the decrease in currently formed corpora lutea was detected at the highest dose in 4 weeks treatment. These findings generally accepted as results in disruption of ovulation. The -reported (Davis et al., 1994) . The prolongation of estrous cycle observed in the present study might be supported by the disruption of ovulation. Therefore, the increases of large atretic follicles and consistently the decrease of currently formed corpora lutea are considered to be treatment-related histopathologic changes. Vacuolation of ovarian stromal cells was observed in the 300 mg/kg and higher groups of both the 2-and 4-week studies; however, abnormal changes in the estrous cycle (prolongation of the mean estrus cycle and irregular estrous cycles) were only observed in the 3,000 mg/kg group of the 4-week study. It is unclear if these ovarian changes have relevance to the abnormal change of the estrous cycle, sex hormone and PPARs. In the female fertility study, prolongation of the estrous cycle and decrease in pregnancy rate were observed at 3,000 mg/kg. Histopathological examination after 2 weeks of administration detected ovarian changes induced by DEHP at the lowest dose of 300 mg/ kg. On the other hand, the fertility study detected changes in the reproductive parameters such as fertility and estrous cycle only at the highest dose of 3,000 mg/kg. In conclusion, histopathological examination of the ovary in a repeated-dose toxicity study with a 2-week administra-DEHP.
